145 related articles for article (PubMed ID: 1094639)
1. HL-A antibody response in patients with acute myelogenous leukaemia treated by immunotherapy.
Klouda TP; Lawler SD; Powles RL; Oliver RT; Grant CK
Transplantation; 1975 Mar; 19(3):245-9. PubMed ID: 1094639
[No Abstract] [Full Text] [Related]
2. Active specific immunotherapy for acute myelogenous leukaemia.
Powles R
Johns Hopkins Med J Suppl; 1974; 3():333-40. PubMed ID: 4609353
[No Abstract] [Full Text] [Related]
3. Immunotherapy for acute myelogenous leukemia using irradiated and unirradiated leukemia cells.
Powles R
Cancer; 1974 Oct; 34(4 Suppl):suppl:1558-62. PubMed ID: 4608692
[No Abstract] [Full Text] [Related]
4. Immunotherapy of acute myelogenous leukemia in man.
Powles R
Natl Cancer Inst Monogr; 1973 Dec; 39():243-7. PubMed ID: 4595324
[No Abstract] [Full Text] [Related]
5. The place of immunological methods of treatment in the management of acute leukaemia.
Powles RL; Russell JA
Hamatol Bluttransfus; 1976; 19():297-304. PubMed ID: 795744
[No Abstract] [Full Text] [Related]
6. Editorial: Immunotherapy for acute myeloid leukaemia.
Lancet; 1974 May; 1(7862):846-7. PubMed ID: 4132795
[No Abstract] [Full Text] [Related]
7. Immunotherapy of leukemia.
Hersh EM; Gutterman JU; Mavligit GM
Med Clin North Am; 1976 Sep; 60(5):1019-42. PubMed ID: 781412
[TBL] [Abstract][Full Text] [Related]
8. Immune complexes in children with leukemia: relationship to disease characteristics and to antibody response to Mycobacterium bovis (BCG) in patients receiving BCG immunotherapy.
Minden P; Odom LF; Tubergen DG; Hardtke MA; Sharpton TR; Rose B; Zlotnick A; Carr RI
Cancer; 1980 Feb; 45(3):460-8. PubMed ID: 6986198
[No Abstract] [Full Text] [Related]
9. Immunotherapy in the treatment of acute leukaemia.
Whittaker JA
Br J Haematol; 1980 Jun; 45(2):187-93. PubMed ID: 6934004
[No Abstract] [Full Text] [Related]
10. Immunotherapy of malignant disease in man.
Russel JA
Acta Neuropathol Suppl; 1975; Suppl 6():227-33. PubMed ID: 1057356
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy.
Granatek CH; Ezaki K; Hersh EM; Keating MJ; Rasmussen S
Cancer; 1981 Jan; 47(2):272-9. PubMed ID: 7006793
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G.
Gutterman JU; Hersh EM; Rodriguez V; McCredie KB; Mavligit G; Reed R; Burgess MA; Smith T; Gehan E; Bodey GP; Freireich EJ
Lancet; 1974 Dec; 2(7894):1405-9. PubMed ID: 4140327
[No Abstract] [Full Text] [Related]
13. Proceedings: Active immunotherapy in acute myeloid leukaemia.
Freeman CB; Taylor GM; Harris R; Geary CG; MacIver JE; Delamore IW
Br J Cancer; 1975 Aug; 32(2):242-3. PubMed ID: 764846
[No Abstract] [Full Text] [Related]
14. Immunological aspects of acute leukemia in man.
Piessens WF; Moloney WC
Eur J Cancer (1965); 1976 Jul; 12(7):511-7. PubMed ID: 782891
[No Abstract] [Full Text] [Related]
15. Chemotherapy and immunotherapy for acute myelogenous leukemia.
Lister TA; Whitehouse JM; Oliver RT; Bell R; Johnson SA; Wrigley PF; Ford JM; Cullen MH; Gregory W; Paxton AM; Malpas JS
Cancer; 1980 Nov; 46(10):2142-8. PubMed ID: 6932992
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of human acute leukemia: antibody response to leukemia-associated antigens.
Baker MA; Falk JA; Taub RN
Blood; 1978 Sep; 52(3):469-80. PubMed ID: 277268
[No Abstract] [Full Text] [Related]
17. Colony-forming ability of marrow from patients receiving immunotherapy during chemotherapy-induced remission in acute myeloid leukaemia.
Gordon MY; Powles RL; Douglas ID
J Clin Pathol; 1977 Jan; 30(1):70-5. PubMed ID: 320231
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for acute myelogenous leukemia.
Powles RL; Lister TA; Crowther D; McElwain T; Alexander P; Fairley GH
Bibl Haematol; 1975; (40):737-49. PubMed ID: 1057948
[TBL] [Abstract][Full Text] [Related]
19. Inability to demonstrate lytic antibodies to autologous leukaemia cells in the sera from remission patients with acute myelogenous leukaemia treated with active specific immunotherapy.
Chapuis BJ; Powles R; Alexander P
Clin Exp Immunol; 1978 May; 32(2):253-8. PubMed ID: 276431
[TBL] [Abstract][Full Text] [Related]
20. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
